Claims
- 1. A method of producing a pharmaceutical composition in a packaging material comprising the steps of
establishing a mould, moulding, in said mould, the packaging material from a melt, whereby the packaging material is provided with at least one cavity, said cavity having at least one side wall and optionally a bottom wall, moulding in a moulding compartment the pharmaceutical composition from a pharmaceutical melt consisting of the ingredients of the pharmaceutical composition having a predetermined temperature, wherein said moulding compartment having a predetermined form being defined by at least a part of said at least one cavity, cooling the pharmaceutical composition, obtaining in the packaging material comprising the pharmaceutical composition having a predetermined form.
- 2. The method according to claim 1, wherein the cavity is an elongated cavity.
- 3. The method according to claim 1, wherein the cavity side wall is defined by the packaging material.
- 4. The method according to claim 1, wherein the moulding compartment is further defined by an insertion means arranged in an open end of the cavity.
- 5. The method according to claim 4, wherein the insertion means is provided with an injection head for injecting the pharmaceutical composition melt into the moulding compartment.
- 6. The method according to claim 2, wherein the predetermined form of the pharmaceutical composition is an elongated form.
- 7. The method according to claim 6, wherein one end of the elongated pharmaceutical composition is plane.
- 8. The method according to claim 6, wherein one end of the elongated pharmaceutical composition is moulded with a tip.
- 9. The method according to claim 8, wherein the tip is defined by a tip mould insert arranged in an open end of the cavity.
- 10. The method according to claim 8, wherein the tip mould insert is arranged in the end of the cavity opposite the insertion means comprising the injection head.
- 11. The method according to claim 8, wherein the cavity is provided with a bottom wall and the tip is defined by the bottom wall.
- 12. The method according to claim 1, wherein the packaging material is moulded from a polymer melt.
- 13. The method according to claim 12, wherein the moulded packaging material is an amorphous polymer material.
- 14. The method according to claim 13, wherein the amorphous polymer material is a cyclic olefin copolymer.
- 15. The method according to claim 1, wherein the glass transition temperature (Tg) of the packaging material is above 100° C.
- 16. The method according to claim 1, further comprising a cooling step comprising cooling the moulded packaging material before moulding the pharmaceutical composition.
- 17. The method according to claim 16, comprising cooling the moulded packaging material to a temperature substantially identical to the predetermined temperature of the pharmaceutical composition melt.
- 18. The method according to claim 1, wherein the moulded packaging material contracts at most 5% after the step of moulding the pharmaceutical composition.
- 19. The method according to claim 1, wherein the packaging material is comprising at least 5 cavities arranged in parallel, said cavities being substantially identical.
- 20. The method according to claim 19, wherein the pharmaceutical compositions of each cavity are moulded simultaneously.
- 21. The method according to claim 1, wherein the packaging material comprises one cavity.
- 22. The method according to claim 21, further comprising a step of assembling two or more packaging materials through a hinging means.
- 23. The method according to claim 1, further comprising moulding a pin being dimensioned to fit into the open end of the cavity after retracting an insertion means.
- 24. The method according to claim 23, wherein the pin is moulded with the packaging material.
- 25. A moulded packaging material comprising
at least one cavity, said cavity having at least one side wall and optionally a bottom wall, and a pharmaceutical composition being moulded in at least a part of said at least one cavity from a melt consisting of the ingredients of the pharmaceutical composition, whereby the pharmaceutical composition is in contact with the cavity side wall in an area being more than half of the surface area of the pharmaceutical composition, wherein the bottom wall functions as a diffusion tight sealing of one end of the cavity, said sealing being moulded from packaging material melt.
- 26. The packaging material according to claim 25, wherein the cavity is an elongated cavity.
- 27. The packaging material according to claim 26, wherein the cavity side wall is defined by the packaging material.
- 28. The packaging material according to claim 25, wherein the pharmaceutical composition has an elongated form.
- 29. The packaging material according to claim 27, wherein one end of the elongated pharmaceutical composition is plane.
- 30. The packaging material according to claim 27, wherein one end of the elongated pharmaceutical composition is provided with a tip.
- 31. The packaging material according to claim 30, wherein the top angle of the tip is in the range of 10° C.-110° C.
- 32. The packaging material according to claim 25, wherein the cavity is provided with a membrane providing a diffusion tight sealing of one end of the cavity.
- 33. The packaging material according to claim 32, wherein the sealing is moulded from packaging material melt.
- 34. The packaging material according to claim 25, wherein the sealing is shaped to correspond to the tip of the pharmaceutical composition.
- 35. The packaging material according to claim 25, further comprising a pin being dimensioned to fit into the open end of the cavity.
- 36. The packaging material according to claim 35, wherein the pin is moulded with the packaging material.
- 37. The packaging material according to claim 35, wherein the pin is providing a diffusion tight sealing of the cavity.
- 38. The packaging material according to claim 25, wherein the packaging material is moulded from a polymer melt.
- 39. The packaging material according to claim 38, wherein the moulded packaging material is an amorphous polymer material.
- 40. The packaging material according to claim 39, wherein the amorphous polymer material is a cyclic olefin copolymer.
- 41. The packaging material according to claim 25, wherein the glass transition temperature (Tg) of the packaging material is above 100° C.
- 42. The packaging material according to claim 25, wherein the moulded packaging material contracts at most 5% after moulding the pharmaceutical composition therein.
- 43. The packaging material according to claim 25, wherein the packaging material is comprising at least 5 cavities arranged in parallel, said cavities being substantially identical.
- 44. The packaging material according to claim 25, comprising at least 5 cavities each being provided with a pharmaceutical composition.
- 45. The packaging material according to claim 44, wherein the packaging material comprises a number of cavities being hinged together forming a cartridge band comprising several cavities.
- 46. The packaging material according to claim 25, wherein the pharmaceutical composition is comprising a therapeutic agent selected from the group consisting of analgesics, antianxiety drugs, antiarthiritic drugs, antibiotic agents, anticholinergics, antidepressants, antidiabetics, antiemetics, antihistaminics, antihypertensive agents, antiinflammatory drugs, antimigraine agents, antiparkinsonism agents, antispasmodesics, antipsychotics, antithrombotic agents, antiviral agents, appetite suppressants, blood factors, cardiovascular drugs, cerebral vasodilators, chemotherapeutic drugs, cholinergic agonists, contraceptives, coronary agents, diuretics, hormonal agents, immunosuppressive agents, growth factors, narcotic antagonists, opiods, peripheral asodilators, tranquilizers, vaccines, immunogenic agents, and immunising agents.
- 47. The packaging material according to claim 25, wherein the therapeutic agent is selected from hormones, lipids, nucleic acids, nucleotides, oligonucleotides, oligosaccharides, organics, peptide mimetics, antibodies, peptides, polysaccharides, and proteins.
- 48. The packaging material according to claim 25, wherein the therapeutic agent is selected from proteins, peptides, and polypeptides, said protein, peptide, or polypeptide being amorphous or crystalline.
- 49. The packaging material according to claim 46, wherein the therapeutic agent is selected from hormones, antidiabetic drugs, growth factors, and blood factors, preferably being a protein selected from insulin, glucagon, growth hormone, blood factor such as FVII and FVIII, GLP-1, EPO, TPO, interferon or derivatives of these proteins.
- 50. A cassette comprising a packaging material as defined in claim 25 and furthermore comprising ejecting means for ejecting the pharmaceutical composition from the cavity.
- 51. The cassette according to claim 50, wherein the ejecting means is a spring-loaded hammer means.
- 52. The cassette according to claim 50, wherein the ejecting means is arranged to exert an ejecting pressure on a pin arranged in one end of the cavity adjacent the pharmaceutical composition.
- 53. A method of administering a dosage of therapeutic agent comprised in a pharmaceutical composition to a patient in need thereof from a cassette as defined in claim 50, comprising
arranging the cassette adjacent the skin of the patient, activating an ejecting means, injecting the pharmaceutical composition comprising the therapeutic agent.
Priority Claims (1)
Number |
Date |
Country |
Kind |
PA 2000 01097 |
Jul 2000 |
DK |
|
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a 35 U.S.C. 371 continuation application of PCT/DK01/00489 filed Jul. 12, 2001 and claims priority under 35 U.S.C. 119 of Danish application PA 2000 01097 filed Jul. 14, 2000 and U.S. provisional application 60/223,802 filed Aug. 8, 2000; the contents of all of the above are fully incorporated herein by reference.
[0002] This application is a continuation, of PCT application serial no. PCT/DK01/00489 filed on Jul. 12, 2001 and claims priority under 35 U.S.C. 119 of Danish application no. PA 2000 01097 filed on Jul. 14, 2000 and U.S. provisional application No. 60/223,802 filed on Aug. 8, 2000, the contents of which are fully incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60223802 |
Aug 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/DK01/00489 |
Jul 2001 |
US |
Child |
10341142 |
Jan 2003 |
US |